|
Neurological diseases | Depression | (1) Correlation with CoQ10 deficiency has been reported | [22, 23] |
Parkinson’s disease | (1) Supplemental CoQ10 improved 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) | [24–30] |
(2) Neuroprotective agent during iron-induced stress in dopaminergic neurons |
(3) Improving mitochondrial defect; therefore, slowing the progressive decline of function |
Progressive supranuclear palsy | (1) Improve mitochondrial energy metabolism | [31, 32] |
(2) Improve cerebral energy metabolism and also clinical problems |
Multiple system atrophy (Shy-DragerSx) | (1) Correlation with CoQ10 deficiency has been reported | [33–36] |
Alzheimer’s disease | (1) Protection of the brain from APP-CTF neurotoxicity reduced beta-amyloid 42 productions and also suppressed oxidative stress | [37–39, 39–41] |
(2) Reversing intracerebroventricular-streptozotocin (ICV-STZ) effects in the hippocampus |
(3) Protective effect against brain atrophy |
Huntington’s disease | (1) Increment of brain ATP levels and improvement in symptoms | [26, 42–46] |
Friedreich’s ataxia | (1) Increased skeletal muscle ATP production and cardiac phosphocreatine to ATP ratio | [47–49] |
(2) Increased fractional shortening in echocardiographic data and slowing the progression of the International Cooperative Ataxia Rating Scale (ICARS) |
Amyotrophic lateral sclerosis | (1) Improvement in survival | [50] |
Migraine headache | (1) The decrease in the number of days with migraine headache | [51–54] |
(2) Reduction in nausea and frequency |
(3) Effective in pediatric migraines as a prophylactic agent |
Down’s syndrome | (1) Correlation with CoQ10 has been reported | [55] |
Cerebellar ataxia | (1) Correlation with CoQ10 deficiency has been reported | [56–59] |
|